APAC Healthcare Weekly (July 20) – Henlius Bio, CanSino, Nippon Shinyaku, JCR, Mesoblast, Sun Pharma
Henlius Bio initiates P3 U.S. trial for cancer drug. FDA rejected Nippon Shinyaku’s new drug filing. JCR partners with Acumen to develop...
774 Views
Hong Kong Single Stock Options Weekly (July 14 – 18): HSI at Fresh Highs But Option Volumes Lag
HSI extends its breakout with strong single stock and sector breadth but option volumes—particularly Calls—showed signs of hesitation.
571 Views
Hong Kong Alpha Portfolio (June 2025)
The Hong Kong Alpha portfolio has significantly outperformed the Hong Kong indexes in June and since inception. Outperformance range is 17% to 23%...
326 Views
APAC Healthcare Weekly (July 13) – Chugai, JCR, Cochlear, CStone, Celltrion, Glenmark, Lupin
Chugai entered inlicensing agreement. JCR Pharma and Glenmark stuck outlicensing deal. Cochlear got new product approval. CStone and Lupin found...
542 Views
Genor Biopharma (6998 HK) - The Reverse Merger Will Unleash the Upside Potential of Valuation
​The merger will boost Genor's valuation and help Edding to go public. Future success hinges on pipeline quality. Valuation expected to reach...
506 Views